New Technologies Used to Diagnose and Treat Lymphomas
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 January 2025) | Viewed by 2116
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit original articles or reviews on lymphomas, one of the most common cancers in the world. There are different types of lymphomas with varied patterns of clinical behavior, prognosis, and responses to treatment. In recent years, new therapeutic strategies have been used and new diagnostic tools have been found, especially using artificial intelligence for diagnoses and treatment responses. However many studies are still needed to optimize diagnostic and therapeutic tools. In the era of immunotherapy, new diagnostic tools are needed to determine the correct response to therapy using artificial intelligence.
This Special Issue aims to showcase new therapeutic strategies increasingly targeted towards the individual patient. In addition, new tools are being used for diagnosis and response to treatments, both from a molecular and imaging perspective, with particular reference to PET/CT and MRI. In this setting, we must not forget artificial intelligence, a new and increasingly fundamental tool used in the diagnostic and therapeutic pathway of lymphomas.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: nuclear medicine, radiology, hematology, immunotherapy, and radiotherapy.
I look forward to receiving your contributions.
Dr. Ambra Buschiazzo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lymphoma
- PET/CT
- immunotherapy
- sarcopenia
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
